Abstract
Objectives and background: Convalescent plasma (CP) has been used worldwide to contrast SARS-CoV-2 infection. Since April 2020, it has also been used in the treatment of patients with COVID-19 in the Veneto region (Italy), along with all the other available drugs and therapeutic tools. Here we report data analysis and clinical results in 1,517 COVID-19 inpatients treated with CP containing high-titre neutralizing anti-SARS-CoV-2 antibodies (CCP). Mortality after 30 days of hospitalization has been considered primary outcome, by comparing patients treated with CCP vs all COVID-19 patients admitted to hospitals of the Veneto region in a one-year period (from April 2020 to April 2021).
Patients and methods: Adult inpatients with a severe form of COVID-19 have been enrolled, with at least one of the following inclusion criteria: 1) tachypnea with respiratory rate (RR) ≥ 30 breaths/min; 2) oxygen saturation (SpO 2 ) ≤ 93% at rest and in room air; 3) partial pressure of oxygen (PaO 2 )/fraction of inspired oxygen (FiO 2 ) ≤ 200 mmHg, 4) radiological picture and/or chest CT scan showing signs of interstitial disease and/or rapid progression of lung involvement. Patients received a maximum of three therapeutic fractions (TFs) of CCP with a neutralizing antibody titre of ≥ 1:160, administered over a period of 3-5 days. If TFs of CCP with titre ≥ 1:160 were unavailable, 2 with antibody titre of ≥ 1:80 have been administered.
Results: Of the 1,517 patients treated with CCP, 209 deceased at the 30-day follow-up (14%). Death was significantly associated with an older age (p<0.001), a longer time of hospitalization before CCP infusion (p<0.001), a greater number of inclusion criteria (p<0.001) and associated comorbidities (p<0.001). Conditions significantly associated with an increased frequency of death were PaO 2 /FiO 2 ≤ 200 (p<0.001) and tachypnea with RR>30 (p<0.05) at entry, concurrent arterial hypertension (p<0.001), cardiovascular disease (p<0.001), chronic kidney disease (p<0.001), dyslipidemia (p<0.05) and cancer (p<0.05). Moreover, factors leading to an unfavorable prognosis were a life-threatening disease (p<0.001), admission to Intensive Care Unit (p<0.001), high flow oxygen therapy or mechanical ventilation (p<0.05) and a chest X-ray showing consolidation area (p<0.001). By analyzing the regional report of hospitalized patients, a comparison of mortality by age group, with respect to our series of patients treated with CCP, has been made. Mortality was altogether lower in patients treated with CCP (14% v. 25%), especially in the group of the elderly patients (23% vs 40%,), with a strong significance (p<0.001). As regards the safety of CCP administration, 16 adverse events were recorded out of a total of 3,937 transfused TFs (0,4%).
Conclusions: To overcome the difficulties of setting up a randomized controlled study in an emergency period, a data collection from a large series of patients with severe COVID-19 admitted to CCP therapy with well-defined inclusion criteria has been implemented in the Veneto region. Our results have shown that in patients with severe COVID-19 early treatment with CCP might contribute to a favourable outcome, with a reduced mortality, in absence of relevant adverse events.
Keywords: Convalescent plasma; Mortality; SARS-CoV-2; Veneto region.
【저자키워드】 convalescent plasma, SARS-CoV-2, Mortality, Veneto region., 【초록키워드】 COVID-19, Treatment, neutralizing antibody, severe COVID-19, Prognosis, mechanical ventilation, Hospitalization, SARS-COV-2 infection, lung involvement, hospital, Cancer, TFS, intensive care unit, Comorbidity, cardiovascular disease, oxygen, Chronic kidney disease, drug, progression, outcome, Italy, hospitalized patients, adverse events, oxygen saturation, anti-SARS-CoV-2 antibody, early treatment, therapeutic, adverse event, Patient, Data analysis, Older age, death, Oxygen therapy, plasma, age, chest X-ray, Neutralizing, Follow-up, disease, Admission, consolidation, Antibody titre, Frequency, Deceased, chest CT scan, COVID-19 patient, Elderly patient, respiratory rate, CCP, tachypnea, Arterial hypertension, Inpatient, Factor, Primary outcome, inclusion criteria, life-threatening, titre, fraction, CCP administration, CCP therapy, randomized controlled study, Administered, Inclusion, objective, radiological, interstitial, Veneto, greater, enrolled, shown, significantly, reduced, treated, condition, contribute, absence, overcome, were recorded, PaO, patients treated, patients with COVID-19, transfused, 【제목키워드】 SARS CoV-2, Italy, convalescent, registry, Inpatient, Veneto, treated,